Chiharu Otani
Kyoto, 6068507, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
MicroRNA-33 inhibition ameliorates muscular dystrophy by enhancing skeletal muscle regeneration.
Journal: EMBO molecular medicine
Published: February 27, 2025
KUS121, a novel VCP modulator, attenuates atherosclerosis development by reducing ER stress and inhibiting glycolysis through the maintenance of ATP levels in endothelial cells.
Journal: Atherosclerosis
Published: November 07, 2024
KUS121, a VCP modulator, has an ameliorating effect on acute and chronic heart failure without calcium loading via maintenance of intracellular ATP levels.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: August 24, 2023
Inhibition of microRNA-33b in humanized mice ameliorates nonalcoholic steatohepatitis.
Journal: Life science alliance
Published: January 05, 2023
microRNA-33 maintains adaptive thermogenesis via enhanced sympathetic nerve activity.
Journal: Nature communications
Published: September 10, 2019
Identification of Differential Roles of MicroRNA-33a and -33b During Atherosclerosis Progression With Genetically Modified Mice.
Journal: Journal of the American Heart Association
Published: June 28, 2019
Homeobox A4 suppresses vascular remodeling by repressing YAP/TEAD transcriptional activity.
Journal: EMBO reports
Published: May 01, 2019
Cardioprotective Effects of VCP Modulator KUS121 in Murine and Porcine Models of Myocardial Infarction.
Journal: JACC. Basic to translational science
Published: March 20, 2019
Showing 1-8 of 8
Last Updated: 09/26/2026